Skip to content
Menu

Vera Therapeutics, Inc. VERA

Full chart Compare
Set alert

Price alert · VERA

All alert types
26.75 USD 0.00 (+0.00%)

Regular-session close

26.10 -0.65 -2.43%

Pre-market · Nov 20, 8:40 AM ET

25.08 Day range 26.99
25.08 52-week range 56.05
YTD
-47.18%
1 year
-4.02%

5D -1.91 (-6.66%)

262728FriMonTueWedThu26.75
Market cap
1.93B
Revenue (ttm)
10.28M
EPS (ttm)
-5.90
Shares out
72.30M
Forward P/E
-6.83
YTD return
-47.18%
1-year return
-4.02%
50-day average
30.58
200-day average
35.87
Enterprise value
1.54B
Volume
1.05M
Avg volume
1.95M
Open
25.60
Previous close
26.75
Day's range
25.08 – 26.99
52-week range
25.08 – 56.05
Beta
1.19
Analysts
Strong Buy
Price target
71.36 (+166.8%)
Earnings date
Feb 25, 2027

Key statistics

Price / sales
188.19
Price / book
5.80
Free cash flow
-244.62M
Total cash
384.04M
Total debt
76.79M
Return on equity
-113.46%
Short % of float
19.11%

Fundamental scorecard

4 of 25 checks passed on VERA’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
VERA Revenue — quarterly 10.28M
VERA Net income — quarterly -93.71M
VERA EPS — quarterly -1.30

Earnings

VERA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-1.46———
Nov 5, 2026Sep 30, 2026-1.62-1.30+0.32+19.75%
Aug 10, 2026Jun 30, 2026-1.58-1.52+0.06+3.80%
May 7, 2026Mar 31, 2026-1.33-1.69-0.36-27.22%
Feb 26, 2026Dec 31, 2025-1.34-1.39-0.05-3.73%
Nov 5, 2025Sep 30, 2025-1.20-1.26-0.06-5.00%

Upgrades / downgrades

VERA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026WedbushmainNeutralNeutral
Nov 6, 2026GuggenheimmainBuyBuy
Nov 6, 2026HC Wainwright & Co.mainBuyBuy
Oct 12, 2026Leerink Partnersinit—Market Perform
Sep 8, 2026JP MorganmainOverweightOverweight
Aug 17, 2026WedbushreitNeutralNeutral

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
veratx.com

News

Your note

Sign in to keep a note on VERA — it syncs with the Stock Master app.

Insider holders

VERA insider holders
InsiderRelationLatest transactionDateShares held
BOMAN NANCY LEE M.D., PH.D.OfficerStock Award(Grant)Aug 2, 202644,987
BRENNER ROBERTOfficerSaleFeb 22, 202650,947
CARTER JASON SOfficerSaleNov 20, 202549,136
ENRIGHT PATRICK G.DirectorPurchaseDec 10, 20255,400,090
FORDYCE MARSHALLChief Executive OfficerConversion of Exercise of derivative securitySep 14, 2026235,244
GRANT SEANChief Financial OfficerSaleFeb 22, 2026119,181

Institution ownership

VERA institution ownership
Holder% heldSharesValueReported
Deep Track Capital, Lp9.68%7,000,000187.25MSep 29, 2026
Blackrock Inc.7.92%5,728,892153.25MSep 29, 2026
Avoro Capital Advisors LLC7.79%5,635,000150.74MSep 29, 2026
Deerfield Management Company, L.P6.00%4,338,778116.06MSep 29, 2026
State Street Corporation4.57%3,301,89388.33MSep 29, 2026
Kynam Capital Management, LP4.15%3,000,00080.25MSep 29, 2026

Fund ownership

VERA fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.67%1,933,72851.73MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.54%1,834,39749.07MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.29%1,654,80644.27MSep 29, 2026
T. Rowe Price New Horizons Fund, Inc.1.40%1,014,45727.14MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund1.21%871,54723.31MSep 29, 2026
T. Rowe Price Health Sciences Fund, Inc.1.08%784,30620.98MJun 29, 2026